Lipodystrophy and nucleoside analogue therapy in HIV-infected patients: Important question, few valid answers [4]

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 1, 2000, Pages 96-97

  Savès, Marianne ^a   Chêne, Geneviève ^a   Suissa, Samy ^b  

^a INSERM   (France)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NUCLEOSIDE ANALOG; STAVUDINE; ZIDOVUDINE;

DRUG EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPID STORAGE; LIPODYSTROPHY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0034275115     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200009010-00016     Document Type: Letter

References (5)

1. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
2. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
3. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
4. Bias and confounding in pharmacoepidemiology
5. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome